119 related articles for article (PubMed ID: 36637424)
21. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
22. FRMD8 targets both CDK4 activation and RB degradation to suppress colon cancer growth.
Yu M; Wu W; Sun Y; Yan H; Zhang L; Wang Z; Gong Y; Wang T; Li Q; Song J; Wang M; Zhang J; Tang Y; Zhan J; Zhang H
Cell Rep; 2023 Aug; 42(8):112886. PubMed ID: 37527040
[TBL] [Abstract][Full Text] [Related]
23. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
24. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
25. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
26. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition.
Guiley KZ; Stevenson JW; Lou K; Barkovich KJ; Kumarasamy V; Wijeratne TU; Bunch KL; Tripathi S; Knudsen ES; Witkiewicz AK; Shokat KM; Rubin SM
Science; 2019 Dec; 366(6471):. PubMed ID: 31831640
[TBL] [Abstract][Full Text] [Related]
27. The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity.
Lin J; Guo D; Liu H; Zhou W; Wang C; Müller I; Kossenkov AV; Drapkin R; Bitler BG; Helin K; Zhang R
Cancer Immunol Res; 2021 Dec; 9(12):1413-1424. PubMed ID: 34848497
[TBL] [Abstract][Full Text] [Related]
28. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
[TBL] [Abstract][Full Text] [Related]
29. The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.
Cabrera MC; Díaz-Cruz ES; Kallakury BV; Pishvaian MJ; Grubbs CJ; Muccio DD; Furth PA
Cancer Prev Res (Phila); 2012 Jun; 5(6):810-21. PubMed ID: 22508966
[TBL] [Abstract][Full Text] [Related]
30. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
31. Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB.
Schade AE; Oser MG; Nicholson HE; DeCaprio JA
Oncogene; 2019 Jun; 38(25):4962-4976. PubMed ID: 30833638
[TBL] [Abstract][Full Text] [Related]
32. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
33. Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6.
Padmanabhan B; Adachi N; Kataoka K; Horikoshi M
J Biol Chem; 2004 Jan; 279(2):1546-52. PubMed ID: 14583612
[TBL] [Abstract][Full Text] [Related]
34. Activation of cyclin D1-Cdk4 and Cdk4-directed phosphorylation of RB protein in diabetic mesangial hypertrophy.
Féliers D; Frank MA; Riley DJ
Diabetes; 2002 Nov; 51(11):3290-9. PubMed ID: 12401721
[TBL] [Abstract][Full Text] [Related]
35. Controversial relationship between the expression of the RB pathway components and RB protein phosphorylation in human breast cancer.
Montanaro L; Vici M; Donati G; Ceccarelli C; Santini D; Treré D; Derenzini M
Histol Histopathol; 2007 Jul; 22(7):769-75. PubMed ID: 17455150
[TBL] [Abstract][Full Text] [Related]
36. S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer.
Mo H; Liu X; Xue Y; Chen H; Guo S; Li Z; Wang S; Li C; Han J; Fu M; Song Y; Li D; Ma F
Mol Cancer; 2022 Aug; 21(1):171. PubMed ID: 36042494
[TBL] [Abstract][Full Text] [Related]
37. Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor.
Tomosugi M; Sowa Y; Yasuda S; Tanaka R; te Riele H; Ikawa H; Koyama M; Sakai T
Cancer Sci; 2012 Dec; 103(12):2139-43. PubMed ID: 22957647
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
[TBL] [Abstract][Full Text] [Related]
39. Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas.
Ghazizadeh M; Jin E; Shimizu H; Fujiwara M; Arai S; Ohaki Y; Takemura T; Kawanami O
Respiration; 2005; 72(1):68-73. PubMed ID: 15753637
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
